Comparison results
| Results: Differences General | ✘Atypical mycobacterial infections | ✘Pigmented villonodular synovitis | |||||||||||||
| Related research | Analogs | Analogs | |||||||||||||
| |||||||||||||||
| Distinctive symptoms | |||||||||||||||
| Register, to see more distinctive signs of diseases and studies | 100% | — | |||||||||||||
| Register, to see more distinctive signs of diseases and studies | — | 79% | |||||||||||||
| erythropenia | 76% | — | |||||||||||||
| bursitis | 25% | 100% | |||||||||||||
| increased | 67% | — | |||||||||||||
| antinuclear factor | — | 70% | |||||||||||||
| atypical mycobacterial infections | 46% | — | |||||||||||||
| pigmented villonodular synovitis | — | 62% | |||||||||||||
| cervical syndrome | 40% | — | |||||||||||||
| arthritis | 20% | 81% | |||||||||||||
| madaroz | 40% | — | |||||||||||||
| oncology | — | 59% | |||||||||||||
| lymphadenitis | 38% | — | |||||||||||||
| joint diseases | 19% | 76% | |||||||||||||
| skin problems | 37% | — | |||||||||||||
| pain in the ankles | — | 51% | |||||||||||||
| bursitis of the elbow joint | 35% | — | |||||||||||||
| radiation damage | — | 49% | |||||||||||||
| impaired lung function | 35% | — | |||||||||||||
| nodules on the joints | — | 49% | |||||||||||||
| leprosy | 34% | — | |||||||||||||
| redness of the joints | — | 46% | |||||||||||||
| infected wounds | 33% | — | |||||||||||||
| pain in the shins | — | 46% | |||||||||||||
| wound | 32% | — | |||||||||||||
| swelling of joints | — | 44% | |||||||||||||
| cubital canal syndrome | 31% | — | |||||||||||||
| take it, take it | — | 43% | |||||||||||||
| lymphadenitis in children | 31% | — | |||||||||||||
| arthritis with pain | — | 43% | |||||||||||||
| the Mantoux reaction | 27% | — | |||||||||||||
| up radiation sickness | — | 42% | |||||||||||||
| immunodeficiency | 27% | — | |||||||||||||
| pain in the foot | — | 42% | |||||||||||||
| pain in the lymph nodes | 25% | — | |||||||||||||
| inflammation | 23% | 65% | |||||||||||||
| medicinal arthropathy | 25% | — | |||||||||||||
| small-point rash | — | 41% | |||||||||||||
| consequences of infection | 25% | — | |||||||||||||
| osteosarcoma | — | 41% | |||||||||||||
| effects of hormone | 25% | — | |||||||||||||
| lymphosarcoma | — | 38% | |||||||||||||
| lower respiratory tract infections | 24% | — | |||||||||||||
| joint pain | — | 37% | |||||||||||||
| chronic granulomatous disease | 24% | — | |||||||||||||
| general swelling does | — | 37% | |||||||||||||
| ARVI | 22% | — | |||||||||||||
| osteoporosis | — | 37% | |||||||||||||
| lymph node damage | 21% | — | |||||||||||||
| radiation therapy | — | 36% | |||||||||||||
| traumatic illness | 20% | — | |||||||||||||
| pain in the legs | — | 36% | |||||||||||||
| tuberculosis | 20% | — | |||||||||||||
| periods of exacerbation | — | 35% | |||||||||||||
| bacteremia | 20% | — | |||||||||||||
| gradual deterioration of the condition | — | 35% | |||||||||||||
| does not tolerate pain | 20% | — | |||||||||||||
| feeling of heat | — | 33% | |||||||||||||
| worse during day | 19% | — | |||||||||||||
| cancer | — | 32% | |||||||||||||
| hypertension | 18% | — | |||||||||||||
| high temperature | — | 32% | |||||||||||||
| necrosis | 18% | — | |||||||||||||
| swelling | — | 31% | |||||||||||||
| periodic illness | — | 31% | |||||||||||||
| consequences of surgery | — | 31% | |||||||||||||
| history of surgery | 35% | 56% | |||||||||||||
| consequences of taking medications | 16% | 29% | |||||||||||||
| papules | 28% | 35% | |||||||||||||
Instructions
Video 
- Introduce new diseases through 🔍 Search and input on the top panel using
- The table shows the most important distinguishing symptoms, tests and diagnoses related to the selected diseases.
- The higher the percentage, the more important this symptom is for the disease and vice versa. At 0%, we can say that this symptom never occurs in the disease.
- The list changes dynamically depending on the data of the current visit in the selection of therapy .
- Click on the percentageto see the suggestions from the original source.
- By using the service, you agree to user agreement.
